Project Grant R01AI203404
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $625K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $511,531 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance HIV vaccine development using a lipid nanodisc platform. The project, designated R01AI192143, addresses challenges in engineering transmembrane HIV envelope glycoprotein (ENV) vaccine candidates by incorporating them into stable lipid nanodiscs using membrane scaffold proteins and...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $249,656 in project grant funding on July 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define and target the adenosine-ADA-1 axis in HIV-specific CD8+ T cell dysfunction. The research addresses persistent viral reservoirs in people living with HIV by investigating how extracellular adenosine and reduced adenosine deaminase-1 expression contribute to impaired antiviral T...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $909,998 on May 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a vaccination strategy against HIV using DNA-lipid nanoparticle technology. The research aims to induce strong and durable humoral and cellular immunity against HIV through DNA-LNP vaccination approaches that combine neutralizing antibody responses with CD8 T cell responses, including tissue-resident memory...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $584,755 for a Project Grant (R01AI192491) on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds the engineering of biomaterial-based dendritic cell therapies for antigen-specific immune tolerance. The project develops sustained-release microparticles incorporating an immunomodulatory combination (PPI9: CEP-33779 and R848) to generate long-lived, potent...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $1,201,718 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate HIV vaccines using DNA and replicon RNA formulations combined with a lipid nanoparticle platform. The research compares two vaccine approaches—DNA/LION liposomes and replicon RNA/LION liposomes—both expressing membrane-bound stabilized HIV envelope trimers, alongside a GAG DNA/LION...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $888,042 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate N332-glycan-independent V3-glycan antibodies as targets for HIV-1 vaccine design. The research develops novel broadly neutralizing antibody responses against HIV-1 envelope protein by studying vaccine candidates that elicit antibodies binding to the V3-glycan epitope...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $889,101 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop enhanced natural killer cell-based strategies targeting HIV reservoirs. The recipient will develop and test tri-specific NK cell engager molecules (TRIKEs) engineered to enhance NK-mediated antibody-dependent cellular cytotoxicity (ADCC) responses against HIV-infected cells....
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $794,984 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support structure-based discovery and development of next-generation soluble CD4 (sCD4) immunotherapeutics for HIV treatment. The funded research targets HIV's obligate dependence on CD4 for viral entry by engineering a new class of potent, broad, and long-acting sCD4-D1-based bifunctional...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $276,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate HIV-1 envelope-C3D constructs on nanoparticles for structure, function, and immunogenicity. Scripps will assess ENV-C3D fusion candidates carrying two and three copies of C3D domains per GP160 subunit (with or without Fc domain) in C57BL/6 and alloy mice. The research will measure germinal...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...